Roberto Gulminetti
A5016317402- Hepatitis C virus research
- HIV/AIDS drug development and treatment
- HIV Research and Treatment
- Hepatitis B Virus Studies
- Liver Disease Diagnosis and Treatment
- HIV/AIDS Research and Interventions
- HIV-related health complications and treatments
- Pneumocystis jirovecii pneumonia detection and treatment
- Systemic Lupus Erythematosus Research
- Cytomegalovirus and herpesvirus research
- Immune Cell Function and Interaction
- Drug-Induced Hepatotoxicity and Protection
- Liver Disease and Transplantation
- Renal Transplantation Outcomes and Treatments
- COVID-19 and healthcare impacts
- Chronic Lymphocytic Leukemia Research
- Reproductive tract infections research
- Antifungal resistance and susceptibility
- Cervical Cancer and HPV Research
- Venous Thromboembolism Diagnosis and Management
- Viral gastroenteritis research and epidemiology
- Blood groups and transfusion
- Pharmacological Effects and Toxicity Studies
- Monoclonal and Polyclonal Antibodies Research
- Diabetes and associated disorders
Istituti di Ricovero e Cura a Carattere Scientifico
2014-2025
University of Pavia
2015-2025
Policlinico San Matteo Fondazione
2013-2024
University of Rome Tor Vergata
2023
Infectious Diseases and the Research Institute
2020
Pharmacy Research UK
2020
University of Turin
2020
Office of Infectious Diseases
2020
Ospedale Amedeo di Savoia
2020
I.R.C.C.S. Oasi Maria SS
2019
Direct-acting antiviral (DAA) agents target HCV proteins; some of these have already been approved for the treatment infection, while others are in development. However, selection DAA-resistant viral variants may hamper treatment. The aim this study was to illustrate potential natural DAA-resistance mutations NS5A and NS5B regions genotypes 1a 1b from DAA-naïve patients. Direct sequencing performed 32 patients infected with genotype 30 1b; all subjects were naïve DAAs. In strains, resistance...
Little is known about the applicability of dual treatments based on integrase inhibitors. We explored combination lamivudine + dolutegravir as an option when switching from standard cART in virologically suppressed patients.In this prospective cohort we enrolled patients previously switched to 3TC DTG who were 18 years or older, with no previous resistance mutations used drugs, having a HIV-RNA <50 copies/ml for 6 months longer, negative HBsAg and stable (>6 months) cART.Ninety-four...
Abstract Background Protease inhibitors (PIs) to treat hepatitis C (HCV) virus infection have been approved and others are under development. Results The aims of this study were illustrate natural polymorphisms in the HCV protease measure frequency PI resistance mutations different genotypes from PI-naïve patients. Direct sequencing NS3/4A was performed 156 patients naïve PIs who infected with genotype 1a (n = 31), 1b 39), 2 30), 3 33) 4 23). Amino acid (aa) substitutions associated found...
Dyslipidemia represents a significant non-infectious comorbidity among people living with HIV. The aim of this study is to evaluate the impact on lipid profile switches from an efavirenz (EFV) or protease inhibitor/ritonavir (PI/r)-based regimen rilpivirine (RPV) once-daily integrase inhibitor-based regimen. We analyzed data SCOLTA prospective database. All patients HIV-RNA < 50 copies/ml in therapy two NRTI + EFV PI/r were included if they switched dolutegravir (group EFV-DTG), elvitegravir...
To compare results of liver stiffness measurements by transient elastography (TE) obtained in our patients population with that used a recently published meta-analysis.This was single center cross-sectional study. Consecutive chronic viral hepatitis scheduled for biopsy at the outpatient ward Infectious Diseases Department were enrolled. TE carried out using FibroScan™ (Echosens, Paris, France). Liver performed on same day as TE, case procedure. Fibrosis staged according to Metavir scoring...
Background There are few real-life data on the potential drug-drug interactions (DDIs) between anti-HCV direct-acting antivirals (DAAs) and comedications used. Aim To assess DDIs of DAAs in HCV-infected outpatients, according to severity liver disease comedication used a prospective multicentric study. Methods Data from patients 15 clinical centers who had started DAA regimen were receiving during March 2015 2016 prospectively evaluated. The for each assigned HepC Drug Interactions...
Abstract Natural resistance-associated substitutions (RASs) are reported with highly variable prevalence across different HCV genotypes (GTs). Frequency of natural RASs in a large Italian real-life cohort patients infected the 4 main HCV-GTs was investigated. NS3, NS5A and NS5B sequences were analysed 1445 HCV-infected DAA-naïve patients. Sanger-sequencing performed by home-made protocols on 464 GT1a, 585 GT1b, 92 GT2c, 199 GT3a, 16 GT4a 99 GT4d samples. Overall, 20.7% (301/1455) showed...
Abstract Background A dolutegravir plus darunavir/cobicistat regimen has been used as a simplified option in heavily treatment-experienced people with HIV (PWH). We report on long-term results of this assessed by treatment discontinuation (TD) for any reason. Methods This was retrospective, observational, multicentre study. PWH started from 1 December 2015 to 31 2022 were included. The primary endpoint the rate TD Survival analysis Kaplan–Meier estimator assess probability over time....
Cardiovascular disease (CVD) is common in people with HIV (PWH), and has great impact terms of morbidity mortality. Several intertwined mechanisms are believed to play a role determining the increased risk CVD, including effect certain antiretrovirals; among these, integrase strand-transfer inhibitors (INSTIs) yet be fully elucidated. We conducted multicenter, observational study comprising 4984 PWH evaluating antiretroviral therapy (ART)-related nature CVD real life settings, both naïve vs....
The emergence of drug-resistance mutations in HIV-1 integrase patients receiving HAART salvage regimens including raltegravir was investigated 11 heavily pretreated (median number treatment failures 12, range 5-22) within an expanded access program Pavia, Italy. RNA levels plasma, CD4(+) T-cell counts and sequencing reverse transcriptase (RT), protease (PR), gp41, genes were performed at baseline after 1, 2, 3, 6, 12 months. median plasma decreased from 7,510 (range 118-407,107) to <50...
This study evaluates the frequency and causes of dolutegravir (DTG) discontinuation along 5 years follow-up, in both antiretroviral treatment (ART)-naive experienced people living with HIV (PLWH). is a prospective multi-center cohort enrolling PLWH on DTG from July 2014 until November 2020. DTG-durability was investigated using Kaplan–Meier survival curve. The Cox proportional-hazards model used for estimating hazard ratio (HR) any cause, adverse events (AEs). Nine hundred sixty-three were...
Sustained virologic response rates have increased dramatically following direct acting antiviral (DAA) therapy in chronic HCV infection. However, resistance-associated substitutions (RASs) may occur either prior to DAA or drug exposure. The aim of this study was determine RASs treatment-failing patients and the role failure treatment. Six hundred twenty were evaluated. Direct sequencing genes performed at breakthrough all 31 failing DAAs, 19 baseline patients. Deep analysis 15/19 detected...
Introduction: Metabolic disorders are common amongst HIV-infected patients. Data from real-life setting on the impact of DTG/ABC/3TC in virologically suppressed patients scarce. Methods: We investigated modification metabolic profile including fasting glucose, lipid and markers insulin resistance (IR) experienced switching a boosted protease inhibitors (bPI) or non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen to prospective, observational, multicenter study. Results:...
Viral load peak and immune activation occur shortly after exposure during acute or early HIV infection (AEHI). We aimed to define the benefit of start antiretroviral treatment (ART) AEHI in terms immunological recovery, virological suppression, discontinuation.
Abstract Background The use of DTG-containing two-drug regimens is one the most promising solutions to need ease management HIV treatment without harming its efficacy and safety. We report long- term results in patients switched, while virologically suppressed, combination dolutegravir (DTG) plus lamivudine (3TC). Methods This a prospective, clinical, uncontrolled cohort enrolling ART-experienced people living with (PLWH) HIV-RNA < 50 copies/ml for 6 months or longer, negative hepatitis B...